Resource id #3DrugId:1d00000050resource(4) of type (mysql result) Drug Search

Main    A    B    C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z    Main   

Drug ID: 1d00000050

Drug Name: Alfa-glucosidase

Generic Names: Lumizyme | Myozyme

Category: Enzyme Replacement Therapy

Legal Status: Non Opioid Prescription only drug


Indication for Mother: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Recommended Dose: The recommended dosage is 20-mg/kg body weight administered every 2 weeks as an intravenous infusion.

Recommended In: This medication is a glycoprotein, prescribed for pompe disease. It works by replacing the enzyme alfa-glucosidase in the body.

Directions For Use: It comes as a solution for injection to be administered by a healthcare provider into the vein.

Storage: Store it in refrigerator (2 to 8C), do not freeze it. Remove the required number of vials from the refrigerator and allow them to reach room temperature prior to reconstitution (approximately 30 minutes).

Dosage Forms: Intravenous injection

Side Effects: Most common- Hives, diarrhea, vomiting, difficulty in breathing, itching, rash, throat and neck pain.

Blood and lymphatic- Swollen glands.

Eye and ENT- Hearing loss, ear discomfort or pain and blurred vision.

Gastrointestinal - Constipation, abdominal pain, indigestion and vomiting.

General - Chest discomfort or pain, injection site reactions, uneasiness and swelling in the extremities.

Immune system- Anaphylaxis, infections and stomach inflammation.

Respiratory - Upper respiratory tract infection, procedural complications and procedural pain.

Metabolic - Decreased potassium level in blood.

Musculoskeletal - Muscle twitching, musculoskeletal pain and musculoskeletal stiffness or tightness.

Central Nervous system- Drowsiness and tremor.

Genitourinary - Kidney stones.

Respiratory - Shortness of breath during exercise and nosebleed.

Skin - Increased sweating.

In Case of Overdose: There have been no reports of overdose with alglucosidase. In clinical trials, patients received doses up to 40 mg/kg of body weight.

Avoid If: Caution should be exercised in patients with history of heart or lung problems, any allergy, who are taking other medications, children, during pregnancy and breastfeeding.

Monitor liver function regularly while taking this medication.

Drug Interaction: No drug interaction or in vitro metabolism studies were performed.

Main    A    B    C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z    Main